In HFpEF with LVEF ≤60%,¹

PARAGON-HF: Prescribe ENTRESTO^® for more of your patients to reduce heart failure hospitalizations^2,3

ENTRESTO reduced total HF hospitalizations and CV death^2,3

In a prespecified subgroup analysis of PARAGON-HF patients with LVEF at or below the median (57%)^†:

ENTRESTO reduced total HF hospitalizations vs valsartan³

Components of the composite end point in patients with LVEF at or below the median (57%)^†:

^†LVEF is a variable measure that can change over time, and the normal range differs according to patient characteristics and method of assessment.
^‡Event rate per 100 patient-years.

ENTRESTO^® is prescribed across the spectrum of patients from HFrEF to HFpEF with LVEF ≤60%. Learn about the 2023 data from PARAGLIDE-HF^1,2,5

PARAGLIDE-HF: THE FIRST AND ONLY HEAD-TO-HEAD STUDY IN STABILIZED HFmrEF AND HFpEF^§ PATIENTS FOLLOWING A WORSENING HF EVENT^5‖

PARAGLIDE-HF: In the total population, ENTRESTO was superior to valsartan in reduction of 
NT-proBNP^5,7,8

TOTAL POPULATION

ENTRESTO DEMONSTRATED A SIGNIFICANT REDUCTION IN NT-proBNP VS AN ARB AT WEEKS 4 AND 8⁵

PRIMARY END POINT WAS MET: Time-averaged proportional change in NT-proBNP over time from baseline to Weeks 4 and 8

• ENTRESTO reduced NT-proBNP by 28% (n=180) compared to 16% with valsartan (n=197), with a proportional difference of 15% (Ratio of change: 0.85; 95% CI: 0.73–0.999; P=.049)

PRESPECIFIED SUBGROUP ANALYSIS: LVEF ≤60%

In PARAGLIDE-HF, the prespecified subgroup analysis was not powered for determining significance of the findings.

PATIENTS ON ENTRESTO HAD A GREATER REDUCTION IN NT-proBNP VS THOSE ON VALSARTAN^5,7,8

PARAGLIDE-HF: Secondary efficacy end points showed numerical differences favoring patients on ENTRESTO⁵

In PARAGLIDE-HF, secondary end points were not powered for determining significance of the findings.

WIN RATIO

WIN RATIO (PRESPECIFIED SUBGROUP ANALYSIS: LVEF ≤60%)

In patients with LVEF ≤60%, the win ratio numerically favored patients on ENTRESTO vs those on valsartan⁵

COMPOSITE CV OUTCOMES END POINT (TOTAL POPULATION)

In PARAGLIDE-HF, secondary end points were not powered for determining the significance of the findings.

A numerically reduced rate in a composite end point of total HF hospitalizations, urgent HF visits,^¶ and CV death was seen in patients on ENTRESTO vs those on valsartan, driven by reduction in HF hospitalizations.⁵

• 17% relative rate reduction in patients on ENTRESTO vs valsartan (NS): RR 0.83 (95% CI: 0.57–1.23); 12.7 ARR^#

WORSENING RENAL FUNCTION COMPOSITE END POINT (TOTAL POPULATION)⁵

In PARAGLIDE-HF, secondary end points were not powered for determining the significance of the findings.

SAFETY PROFILE

PARAGLIDE-HF: ADVERSE EVENTS OF SPECIAL INTEREST⁵

• No new safety signals were identified⁵

• The exposure-adjusted incidence rates of serious adverse events were 103 (122.2 per 100 patient treatment years) for the ENTRESTO group and 103 (122.2 per 100 patient treatment years) for the valsartan group

• There were 18 deaths in the ENTRESTO group (10 CV) and 26 deaths in the valsartan group (18 CV) 

PARAGLIDE-HF INCLUDED A DIVERSE RANGE OF US AND CANADIAN PATIENTS WHO WERE REFLECTIVE OF THOSE SEEN IN REAL-WORLD PRACTICE^5,10,11

In the total patient population,^5,7

• 52% were female

• 30% were of non-White race/ethnicity (22% were Black)

• 69.5% were randomized in-hospital following stabilization (30.5% out of hospital)

• 33% had no prior history of HF

SELECT PATIENT DEMOGRAPHICS^5,7

^§PARAGLIDE-HF defined HFmrEF and HFpEF as patients with LVEF >40%. The median LVEF was 55%. LVEF is a variable measure that can change over time, and the normal range differs according to patient characteristics and method of assessment.
^‖Worsening HF event was defined as an HF hospitalization, emergency department visit, or out-of-hospital urgent HF visit, all requiring IV diuretics.
^¶An urgent HF visit was defined as an adjudicated emergency department visit or an urgent clinic visit requiring IV diuretics and not requiring overnight hospitalization.^12
#Exposure-adjusted rate per 100 patient-years.
**The worsening renal function adverse event of special interest was defined as an increase in serum creatinine of ≥0.5 mg/L and worsening of the eGFR (mL/min/1.73 m²) by ≥25%.

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.²